**Peripartum Outcomes After Combined Myo-inositol, Probiotics, Micronutrient Supplementation from Preconception: NiPPeR RCT**

**Condensation:**

A myo-inositol, probiotic and micronutrient supplement starting preconception shortened second stage of labor, reduced operative delivery for delayed second stage and decreased postpartum blood loss.

**Short Title**: Nutritional supplementation and peripartum outcomes

**AJOG at a Glance**:

A. Why was the study conducted?

* To assess if a combined myo-inositol, probiotic and micronutrient supplement, starting preconception and continued throughout pregnancy, could improve peripartum outcomes, analyzed as secondary outcomes of a randomized controlled trial.

B. What are the key findings?

* Nutritional intervention reduced the duration of the second stage of labor, clinician intervention for delay in the second stage and postpartum blood loss.

C. What does this study add to what is already known?

* We previously reported that this multi-micronutrient supplementation reduced the risk of preterm delivery, preterm pre-labor rupture of membranes and major postpartum hemorrhage. Now we provide new evidence that nutritional supplementation starting preconception could also shorten the second stage of labor, lower the risk of operative delivery for delayed second stage and decrease postpartum blood loss.

**Blinded Disclosure of Interests**

Several authors report grants from Société Des Produits Nestlé S.A. during the conduct of the study, and are co-inventors on patent filings by Nestlé S.A. relating to the NiPPeR intervention or its components. A few authors are part of an academic consortium that has received grants from Abbott Nutrition, Nestlé S.A., Danone and Benevolent AI Bio Ltd outside the submitted work. One has received reimbursement and honoraria into her research funds from Nestlé S.A. for speaking at a conference. Another has received reimbursement for speaking at conferences sponsored by companies selling nutritional products. All other authors declare no competing interests.

**Keywords**: assisted delivery, blood loss, cesarean section, delay in second stage of labor, delivery outcomes, instrumental delivery, labor progress, operative delivery, postpartum hemorrhage, pregnancy.

**Abstract**

*Background:* Evidence that nutritional supplementation before and during pregnancy improves peripartum outcomes is sparse. In the Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR) trial we previously reported that a combined myo-inositol, probiotics and micronutrient supplement starting preconception showed no difference in the primary outcome of gestational glycemia, but did reduce the risk of preterm delivery, preterm pre-labor rupture of membranes and major postpartum hemorrhage.

*Objective:* To examine the hypothesis that a reduction in major postpartum hemorrhage following a combined nutritional (myo-inositol, probiotics and micronutrient) intervention is linked with promotion of labor progress and reduced operative delivery.

*Study Design:* This double-blind randomized controlled trial recruited from the community 1729 UK, Singapore and New Zealand women aged 18-38 years planning conception between 2015-2017. Here, the effects of the nutritional intervention compared with a standard micronutrient supplement (control), taken preconception and throughout pregnancy, on the secondary outcomes of peripartum events were examined using multinomial, Poisson and linear regression adjusting for site, ethnicity and important covariates.

*Results:* Of the women who conceived and progressed beyond 24 weeks’ gestation with a singleton pregnancy (n=589), 583 (99%) provided peripartum data. Between women in the intervention (n=293) and control (n=290) groups, there were no differences in rates of labor induction, oxytocin augmentation during labor, instrumental delivery, perineal trauma and intrapartum cesarean section. While duration of the first stage of labor was similar, the second-stage duration was 20% shorter in the intervention group compared with controls [adjusted mean difference -12.0 (95%CI -22.2, -1.2) minutes, p=0.029], accompanied by a reduction in operative delivery for delayed second-stage progress [adjusted risk ratio 0.61 (0.48, 0.95); p=0.022]. Estimated blood loss was 10% less with intervention compared with control [adjusted mean difference -35.0 (-70.0, -3.5) ml, p=0.047], consistent with previous findings of reduced postpartum hemorrhage.

*Conclusion:* Supplementation with a specific combination of myo-inositol, probiotics and micronutrients starting preconception and continued in pregnancy reduced both the duration of the second stage of labor and the risk of operative delivery for delay in the second stage, and reduced blood loss at delivery.

**Introduction**

Poor labor progress is the commonest indication for operative delivery, including instrumental vaginal delivery and cesarean section, which are associated with higher morbidity and mortality for mother and baby.1-3 One major complication of prolonged labors and operative deliveries is postpartum hemorrhage (PPH),4 mostly due to tissue trauma from tears and incisions, and uterine atony post-delivery.8 Despite increased use of uterotonics prophylactically, PPH remains the leading cause of maternal mortality in low resource settings and accounts for almost a quarter of maternal deaths globally.5

Effective uterine contractions in conjunction with optimal fetal head positioning and an adequately sized/shaped pelvis, are fundamental to achieving normal labor progress and vaginal birth.6 With poor labor progress, synthetic oxytocin is commonly administered to augment labor7 but this is associated with uterine hyperstimulation, uterine rupture and fetal hypoxia, despite close monitoring. Therefore, there is a need to find complementary approaches to improve uterine contractility peripartum to reduce the risk of prolonged labor, operative delivery for poor progress, and PPH.

Micronutrient status has been associated with labor progress and postpartum bleeding. A study found nulliparous women delivered by cesarean section for labor dystocia had lower serum vitamin D concentrations compared with those who delivered vaginally,20,21 while there is weak evidence that vitamin D supplementation may reduce severe PPH.22 Meanwhile, low zinc levels have been associated with prolonged labor26 and PPH;27 however, a Cochrane review concluded that zinc supplementation did not improve maternal outcomes.28 Whether supplementation with a combination of micronutrients could reduce peripartum risks are unclear as few studies collected such data.

The NiPPeR randomized controlled trial (RCT)29 of a nutritional intervention containing myo-inositol, probiotics and enhanced micronutrients, with the primary outcome of maintenance of euglycaemia during pregnancy, found no difference in gestational glycaemia between the intervention arm and the control arm, who received a standard micronutrient supplement.16 However, there was a significant reduction in preterm delivery, preterm pre-labor rupture of membranes and major PPH (adjusted relative risk 0.44) with the intervention compared with controls. The objective of this further study is to compare in more depth the peripartum outcomes of the two study arms and examine differences that may contribute to the reduction in major PPH. We hypothesized that through the promotion of effective uterine contractility, reflected by improved labor progress and reduced usage of oxytocin augmentation, the intervention could reduce operative delivery rates and decrease postpartum blood loss.

**Materials and Methods**

The trial was registered on 15th July 2015 (<https://www.clinicaltrials.gov/ct2/show/>NCT02509988), with first participant enrolment on 3rd August 2015. Our trial was approved by the United Kingdom, Singapore and New Zealand research ethics services at each site. Southampton: Health Research Authority NRES Committee South Central Research Ethics Committee (REC) reference 15/SC/0142, approved 22 April 2015. Singapore: National Healthcare Group Domain Specific Review Board reference 2015/00205, approved 11 June 2015. New Zealand: Health and Disability Ethics Committee (HDEC) reference 15/NTA/21, approved 30 June 2015. All participants provided written informed consent.

*Trial study design*

Women planning a pregnancy were recruited (n=1729) from the community across 3 sites: New Zealand, UK and Singapore between 2015-2017. The study protocol and details of the NiPPeR supplements were previously published,29 in accordance with CONSORT guidelines. Briefly, participants were randomized by an electronic database in a 1:1 ratio to intervention (n=870) or control (n=859) arms, with stratification by site and ethnicity to ensure balanced allocation. Exclusion criteria were pregnancy/lactation at recruitment, assisted conception (apart from taking clomiphene or letrozole alone), serious food allergy, pre-existing diabetes mellitus, use of hormonal contraception or taking metformin, systemic steroids, anticonvulsants or treatment for HIV, Hepatitis B or C in the past month. Supplements from both arms contained folic acid, iron, calcium, iodine and β-carotene; the intervention additionally included myo-inositol, vitamin D, riboflavin, vitamin B6, vitamin B12, zinc and probiotics (*Lactobacillus rhamnosus* and *Bifidobacterium animalis sp. lactis*).29 Supplements were consumed twice daily from preconception following randomization until delivery. Participants and all study personnel remained blinded to treatment allocation until all pregnancy, delivery and neonatal data had been collected, and analysis of the primary outcome completed. This sub-study of singleton pregnancies delivering beyond 24 weeks’ gestation is an analysis of peripartum events pre-specified as secondary outcomes of the trial.

*Delivery outcomes*

Clinical data, including peripartum events, were abstracted from medical records prospectively. Indications for instrumental vaginal delivery and cesarean section were collected, including documented delay in the first and second stages of labor as defined by the attending obstetric team. For participants with available timings of each stage of labor, a delay in the second stage of labor was also objectively defined according to the American College of Obstetricians and Gynecologists (ACOG)30: second stage of >2h without or >3h with epidural in nulliparous women, and >1h without or >2h with epidural in parous women. “Delay in second stage” for this study included cases defined by the attending obstetric team or meeting ACOG definitions. A prolonged third stage of labor was defined as >30 minutes’ duration.31 Perineal trauma included significant genital tract lacerations, episiotomy with complications, and third/fourth degree tears. Total estimated blood loss at delivery was taken as recorded in routine medical documentation. Major PPH was defined as estimated blood loss >1000ml in the immediate postpartum period, whilst minor PPH as estimated loss of 500-1000ml.32 Macrosomia was defined as birthweight >4000g.

*Statistical analysis*

Durations of the first, second and third stages of labor, and total blood loss were loge transformed to achieve approximately Normal distributions for analyses. Multinomial (mutually exclusive outcomes), Poisson (categorical outcomes) and linear (continuous outcomes) regression analyses were performed as appropriate, with adjustment for study site and ethnicity (the stratification factors; “basic model”), and for covariates imbalanced between study arms or important factors with prognostic influence on outcomes based on existing literature, specifically maternal age, pre-pregnancy body mass index (BMI), household income (in deciles; marker of socioeconomic status), parity (nulliparous or parous), history of previous cesarean section and smoking (“fully-adjusted model”). For outcomes involving duration of labor and oxytocin-use, additional covariates included epidural analgesia and labor induction, respectively. Loge-transformed coefficient values are also presented as the anti-log equivalent, calculated based on the median value among controls. No imputation was performed for missing data. With these analyses of secondary outcomes, emphasis was placed on the magnitude of effect and 95% confidence interval (CI), with a p-value <0.05 deemed statistically significant. The interaction-term (study group\*parity) was introduced into models to seek potentially different effects by parity. *A priori* sensitivity analyses were conducted excluding preterm deliveries, and those where the actual duration of second stage was not recorded, hence cannot be objectively classed by ACOG definitions for delay in second stage.

*Data Sharing*

Individual participant data may be shared upon reasonable requests subject to approval by the trial management group and trial consultative panel.

**Results**

*Participant characteristics*

Of the women who conceived and fulfilled the study criteria (Figure 1), 588 had a live singleton birth between April 2016 to January 2019, with 583 (99%) providing peripartum data (293 intervention, 290 control). Baseline characteristics were balanced across study groups, except for more nulliparity among controls (Table 1).

*Labor onset and mode of delivery*

Overall, analyses found no differences between control and intervention groups in the proportions of women undergoing induction of labor, instrumental vaginal delivery and cesarean section, both in labor and without labor (Supplementary Table 1). Indications for labor induction (Supplementary Table 2) and for operative delivery (Supplementary Table 1) were similar between study groups.

*Labor progress*

Among those who experienced labor, duration of the first stage (Figure 2A) and the risk of delay in the first stage requiring cesarean section (Figure 2B) were similar between study groups. In contrast, among women who reached the second stage of labor, duration of the second stage was 20% shorter with the intervention compared with controls [fully-adjusted mean difference (aMD) -0.20 (95% CI: -0.37, -0.02) loge minutes; equivalent to -12.0 (-22.2, -1.2) minutes, p=0.029; Figure 2A], along with a reduction in the risk of delay in the second stage [fully-adjusted relative risk (aRR) 0.68 (0.48, 0.95), p=0.026, Figure 2B]. Importantly, the risk of requiring operative delivery because of a delayed second stage was also reduced in the intervention group [aRR 0.61 (0.40, 0.93), p=0.022, Figure 2B]. Epidural take-up was similar between groups and did not account for the difference in labor progression (Figure 2B). The shortened second stage of labor with intervention was also not due to differences in iatrogenic curtailment of labor by operative delivery for indications unrelated to delayed progress that could have occurred earlier during the second stage [aRR 1.3 (0.57, 2.93), p=0.532].

A similar proportion in both study groups received oxytocin, even after accounting for labor induction (Figure 2B). In analyses confined to those who had spontaneous labor-onset where oxytocin use would be limited to the purpose of labor-augmentation, there was a suggestion that the intervention reduced requirement for oxytocin augmentation in the basic model, but this effect was attenuated following additional covariate adjustment, largely due to confounding by parity.

Among women who delivered vaginally, no study group differences were observed in the duration of the third stage of labor (Figure 2A) or in prolonged third stage, with similar proportions choosing physiological management (Figure 2B).

*Blood loss at delivery*

The previously reported risk reduction in major PPH with the intervention is now further supported by a finding of 10% reduction in estimated blood loss [aMD -0.10 (-0.20, -0.01) loge ml; equivalent to -35.0 (-70.0, -3.5) ml; p=0.047], with fewer women requiring a blood transfusion in the intervention group compared with controls (0.3% vs 2.5%) (Table 2). However, there was no significant difference in the overall incidence of any PPH (>500ml) between study groups [aRR 1.09 (0.78, 1.53); p=0.62].

To examine potential pathways underlying the intervention effect of reduced postpartum blood loss, for the purposes of hypothesis generation, we explored other risk factors for PPH additional to mode of delivery and length of labor. Considering the whole cohort, there were no study group differences in hemorrhage before or during labor, placental/cord anomalies, pre-labor rupture of membranes (combined term and preterm; associated with possible uterine infection/inflammation), and significant perineal trauma (Supplementary Figure 1). However, among the 33 cases of major PPH some of these events had a somewhat lower incidence in the intervention group (Supplementary Table 3).

*Interaction and sensitivity analyses confirmed robustness of findings*

Non-significant interactions between study group and parity for the outcomes of second stage duration, operative delivery for delayed second stage and estimated blood loss suggest similar intervention effects in nulliparous and parous women. Since the intervention reduced preterm births,16 which may influence peripartum outcomes, sensitivity analyses were conducted excluding all preterm births (<37 weeks’ gestation; n=44); the analyses demonstrated similar results, with the intervention shortening second stage duration by 23% and reducing blood loss by 10% (Supplementary Table 4). Excluding cases where the actual duration of second stage was not recorded (n=19) yielded similar results for delay in second stage requiring operative delivery (aRR 0.62 (0.41 to 0.95), p=0.026).

**Comments**

*Principal Findings*

Supplementation with a specific combination of myo-inositol, probiotics and enhanced micronutrients starting preconception and continued throughout pregnancy reduced both the duration of the second stage of labor and the risk of operative delivery for delay in the second stage, accompanied by decreased postpartum blood loss, consistent with our previous report of a reduction in the incidence of major PPH.

*Results in context*

With the exception of vitamin D, previous trials of antenatal supplementation separately with myo-inositol, probiotics or the specific micronutrients studied here (vitamins B2, B6, B12, D, zinc) have not reported reductions in duration of labor nor in estimated postpartum blood loss.15-17 28,34-36 A reduction in the incidence of severe PPH from 17% to 12% (p<0.01) in a vitamin D trial was considered by the authors to be a spurious finding resulting from potential misclassification.34 Labor progress was not reported in any previous antenatal supplementation studies, possibly due to the data not being collected as these events were not pre-specified outcomes, rather than there being no effect. It is possible that we observed an effect with the NiPPeR intervention because of the additive or synergistic effects of the various components.

*Clinical Implications*

Factors associated with increased postpartum blood loss include a raised BMI and higher parity (both adjusted for in our analyses), fetal macrosomia, operative deliveries, intrapartum cesarean section (rather than without labor), a prolonged labor, physiological third stage of labor, genital tract/perineal trauma, placental/cord anomalies (e.g. previa, accreta, velamentous insertion), uterine infections, and retained products of conception. Whilst among those who suffered a major PPH some of these events featured more prominently in the control group, analyses of the whole cohort suggest that the overall reduction in blood loss in the intervention group could not be attributed to a general reduction in any of these except for a reduced risk of a prolonged second stage and operative delivery for delayed second stage. It is likely that there are other factors not recorded in the trial that could have also contributed to decreased postpartum blood loss. Possibilities include changes in blood coagulation and subclinical intrauterine infections or inflammation, which were not measured in our study. Events such as pre-labor rupture of membranes (PROM) may be proxy markers of the latter, but combined term and preterm PROM occurred at similar rates between intervention and control arms despite a previously reported reduction in exclusively preterm PROM with the NiPPeR intervention (aRR 0.39).16 Further, the exclusion of preterm cases in sensitivity analyses did not alter results of reduced blood loss. Thus, it is likely that subclinical infection/inflammation is not a major contributor to our findings. No participants had known coagulopathies, and the six participants who took aspirin or clexane as prophylaxis against pre-eclampsia or venous thromboembolism within 7 days prior to delivery did not experience major PPH. Overall, mean birthweights and macrosomia rates were also similar between study groups16 and cannot explain the reduction in blood loss.

The trial was conducted in high-resource settings with deliveries occurring in well-equipped and professionally-staffed units where risk of peripartum adversity is already low. Moreover, the recruited population were generally healthy and well-nourished, so it is notable that a nutritional supplement was still able to improve some peripartum outcomes further. From a women’s perspective a 20-minute shortening of the second stage would be welcomed. At an institutional level, with constant pressure to increase resource-efficiency, this would have cumulative significance for labor ward management.

Documented timings of different stages of labor and estimates of blood loss show some subjectivity in routine medical record keeping, which could obscure biological associations. Despite these limitations, the mutually supportive findings that the intervention group had a lower incidence of delay in the second stage of labor alongside an overall reduction in the length of the second stage of labor, as well as a lower incidence of major PPH accompanied by an overall reduction in total estimated blood loss, reduces the likelihood that these are spurious findings.

Since peripartum events were not primary outcomes of the trial, the study was not statistically powered to detect differences in labor length or blood loss at delivery, and the relatively modest sample size and number of events increased the possibility of types 1 and 2 statistical errors. Thus, findings should not be used to infer definitive treatment effects until further additional evidence is generated.

*Research Implications*

The mechanism of effect of the supplement, and which components either individually or in combination could be mediating the shortening of the second stage and reduced blood loss, are topics for further research. Observational and mechanistic studies in pre-clinical models and in human tissues provide clues to the potential underlying pathways involved. Zinc is an important co-factor in promoting blood coagulation,27 and low zinc levels are associated with PPH. Several of the components including myo-inositol,11 B-vitamers,23 vitamin D37,38 and zinc24,25, have demonstrated a role in the regulation of myometrial contractility. For example, myo-inositol (a naturally-occurring carbohydrate present ubiquitously in cells and enriched in fruits, grains, and nuts9,10) can stimulate contraction of the myometrium from non-pregnant rats *ex-vivo* by facilitating the use of extracellular calcium;11 a mechanism similar to one described for oxytocin.12 Zinc-containing proteins regulate expression of oxytocin-induced contractile-associated factors in human myometrium.24 Altered regulation of the general uteroplacental environment by inflammation, chemocytokines, eicosanoids and growth factors, which all play key roles in governing labor progress, could also be involved. After all, outside the context of pregnancy, myo-inositol, probiotics and micronutrients are known to impact such factors.39,40

The postulation that the intervention could facilitate myometrial contractility is not inconsistent with our previous finding of reduced preterm delivery. Facilitation of labor progress at term is likely a distinct phenomenon to the triggers of premature onset of labor, and it is plausible that various components of the intervention could promote the former yet suppress the latter. Even if myometrial contractility is facilitated, our inability to detect any possible difference in first stage duration may be due to imprecision in estimating the timing of labor onset, which frequently occurs prior to hospital admission. Whereas the start of the second stage of labor, and hence its duration, is generally more precisely determined as women are mostly already admitted onto the labor ward.

*Strengths and Limitations*

The robust conduct of this double-blind RCT, which included prospectively collected data and minimization of residual confounding through randomization, with external oversight by an independent data monitoring and trial steering committee, is a strength. Over 96% of women showed good adherence defined *a priori* as supplement intake greater than 60% averaged from recruitment to delivery.16 Even though recruitment occurred across three different countries with inclusion of multiple ethnicities, generalizability to the global population is limited by the lack of African and Amerindian women, in particular.

*Conclusions*

A supplement containing myo-inositol, probiotics and micronutrients starting preconception and continued throughout pregnancy reduced the length of the second stage of labor, operative delivery for delayed second stage, and blood loss at delivery. This needs confirmation by specifically designed clinical trials to better understand the underlying mechanisms and how nutritional supplementation may best be incorporated into clinical practice to improve peripartum outcomes.

**References**

1. Hidalgo-Lopezosa P, Hidalgo-Maestre M, Rodriguez-Borrego MA. Labor stimulation with oxytocin: effects on obstetrical and neonatal outcomes. Rev Lat Am Enfermagem 2016;24:e2744.

2. Orji E. Evaluating progress of labor in nulliparas and multiparas using the modified WHO partograph. Int J Gynaecol Obstet 2008;102:249-52.

3. Spong CY, Berghella V, Wenstrom KD, Mercer BM, Saade GR. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 2012;120:1181-93.

4. Burrows LJ, Meyn LA, Weber AM. Maternal morbidity associated with vaginal versus cesarean delivery. Obstet Gynecol 2004;103:907-12.

5. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014;2:e323-33.

6. Ebrahimzadeh Zagami S, Golmakani N, Saadatjoo SA, Ghomian N, Baghbani B. The shape of uterine contractions and labor progress in the spontaneous active labor. Iran J Med Sci 2015;40:98-103.

7. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst Rev 2013:CD007123.

8. Nyflot LT, Stray-Pedersen B, Forsen L, Vangen S. Duration of labor and the risk of severe postpartum hemorrhage: A case-control study. PLoS One 2017;12:e0175306.

9. Colodny L, Hoffman RL. Inositol--clinical applications for exogenous use. Altern Med Rev 1998;3:432-47.

10. Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annual review of nutrition 1986;6:563-97.

11. Çelik Kavak E, Kacar E, Kavak SB, Bulmus O, Serhatlioglu I, Tektemur A. Myoinositol Causes Myometrial Contractions in Isolated Non-Pregnant Rat Myometrium. Eastern Journal Of Medicine 2018;23:65-70.

12. Phaneuf S, Europe-Finner GN, Carrasco MP, Hamilton CH, Lopez Bernal A. Oxytocin signalling in human myometrium. Adv Exp Med Biol 1995;395:453-67.

13. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011;15:931-6.

14. Formoso G, Baldassarre MPA, Ginestra F, Carlucci MA, Bucci I, Consoli A. Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. Diabetes Metab Res Rev 2019;35:e3154.

15. Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-63.

16. Godfrey KM, Barton SJ, El-Heis S, et al. Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. Diabetes Care 2021.

17. Santamaria A, Alibrandi A, Di Benedetto A, et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. Am J Obstet Gynecol 2018;219:300 e1-00 e6.

18. Cyprian F, Lefkou E, Varoudi K, Girardi G. Immunomodulatory Effects of Vitamin D in Pregnancy and Beyond. Front Immunol 2019;10:2739.

19. Vienonen A, Miettinen S, Blauer M, et al. Expression of nuclear receptors and cofactors in human endometrium and myometrium. J Soc Gynecol Investig 2004;11:104-12.

20. Thomsen CR, Milidou I, Hvidman L, Khalil MR, Rejnmark L, Uldbjerg N. Vitamin D and the risk of dystocia: A case-control study. PLoS One 2020;15:e0240406.

21. Tous M, Villalobos M, Iglesias L, Fernandez-Barres S, Arija V. Vitamin D status during pregnancy and offspring outcomes: a systematic review and meta-analysis of observational studies. Eur J Clin Nutr 2020;74:36-53.

22. Palacios C, Kostiuk LK, Pena-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2019;7:CD008873.

23. Duplessis M, Girard CL, Santschi DE, Laforest JP, Durocher J, Pellerin D. Effects of folic acid and vitamin B12 supplementation on culling rate, diseases, and reproduction in commercial dairy herds. J Dairy Sci 2014;97:2346-54.

24. Renthal NE, Chen CC, Williams KC, Gerard RD, Prange-Kiel J, Mendelson CR. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. Proc Natl Acad Sci U S A 2010;107:20828-33.

25. Dura Trave T, Puig Abuli M, da Cunha Ferreira RM, Villa Elizaga I. Effect of zinc nutrition on parturition and postpartum in the rat. Gynecol Obstet Invest 1984;18:275-80.

26. Lazebnik N, Kuhnert BR, Kuhnert PM, Thompson KL. Zinc status, pregnancy complications, and labor abnormalities. Am J Obstet Gynecol 1988;158:161-6.

27. Vu TT, Fredenburgh JC, Weitz JI. Zinc: an important cofactor in haemostasis and thrombosis. Thromb Haemost 2013;109:421-30.

28. Carducci B, Keats EC, Bhutta ZA. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database Syst Rev 2021;3:CD000230.

29. Godfrey KM, Cutfield W, Chan SY, Baker PN, Chong YS, NiPPeR Study Group. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials 2017;18:131.

30. American College of Obstetrics Gynecology Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin Number 49, December 2003: Dystocia and augmentation of labor. Obstet Gynecol 2003;102:1445-54.

31. Combs CA, Laros RK, Jr. Prolonged third stage of labor: morbidity and risk factors. Obstet Gynecol 1991;77:863-7.

32. Mavrides E, Allard S, Chandraharan E, et al. Prevention and Management of Postpartum Haemorrhage: Green-top Guideline No. 52. BJOG 2017;124:e106-e49.

33. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods 2010;15:309-34.

34. Cooper C, Harvey NC, Bishop NJ, et al. Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4:393-402.

35. Jarde A, Lewis-Mikhael AM, Moayyedi P, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2018;18:14.

36. Salam RA, Zuberi NF, Bhutta ZA. Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. Cochrane Database Syst Rev 2015:CD000179.

37. Thota C, Farmer T, Garfield RE, Menon R, Al-Hendy A. Vitamin D elicits anti-inflammatory response, inhibits contractile-associated proteins, and modulates Toll-like receptors in human myometrial cells. Reprod Sci 2013;20:463-75.

38. Thota C, Laknaur A, Farmer T, Ladson G, Al-Hendy A, Ismail N. Vitamin D regulates contractile profile in human uterine myometrial cells via NF-kappaB pathway. Am J Obstet Gynecol 2014;210:347 e1-47 e10.

39. Samuel TM, Sakwinska O, Makinen K, Burdge GC, Godfrey KM, Silva-Zolezzi I. Preterm Birth: A Narrative Review of the Current Evidence on Nutritional and Bioactive Solutions for Risk Reduction. Nutrients 2019;11.

40. Watkins OC, Yong HEJ, Sharma N, Chan SY. A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy. Crit Rev Food Sci Nutr 2020:1-49.

**Table 1: Baseline characteristics of participants providing peripartum data**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Whole cohort** | | **Underwent labor** | | **Reached second stage of labor** | |
| **Characteristic** | **Control**  **(n=290)** | **Intervention**  **(n=293)** | **Control**  **(n=249)** | **Intervention**  **(n=259)** | **Control  (n=215)** | **Intervention**  **(n=220)** |
| **Age [years; mean (SD)]** | 30.1 (3.3) | 30.6 (3.3) | 29.8 (3.2) | 30.4 (3.3) | 29.7 (3.2) | 30.5 (3.3) |
| **Pre-pregnancy BMI [kg/m2; median (IQR)]** | 23.7  (21.3 to 27.5) | 23.6  (21.2 to 26.1) | 23.6  (21.3 to 27.5) | 23.4  (21.0 to 25.7) | 23.3  (21.0 to 26.7) | 23.4  (21.0 to 25.5) |
| **Study site, n (%)** |  |  |  |  |  |  |
| UK | 93 (32.1) | 96 (32.8) | 78 (31.3) | 83 (32.1) | 70 (32.6) | 70 (31.8) |
| SG | 81 (27.9) | 85 (29.0) | 74 (29.7) | 76 (29.3) | 68 (31.6) | 67 (30.5) |
| NZ | 116 (40.0) | 112 (38.2) | 97 (39.0) | 100 (38.6) | 77 (35.8) | 83 (37.7) |
| **Ethnicity, n (%)** |  |  |  |  |  |  |
| White Caucasian | 168 (58.0) | 177 (60.4) | 139 (55.8) | 156 (60.2) | 117 (54.4) | 133 (60.5) |
| Chinese | 73 (25.2) | 73 (24.9) | 66 (26.5) | 64 (24.7) | 62 (28.8) | 56 (25.5) |
| South Asian | 14 (4.8) | 16 (5.4) | 13 (5.3) | 12 (4.6) | 11 (5.1) | 9 (4.0) |
| Malay | 12 (4.1) | 11 (3.8) | 11 (4.4) | 11 (4.3) | 10 (4.7) | 11 (5.0) |
| Other | 23 (7.9) | 16(5.4) | 20 (8.0) | 16 (6.2) | 15 (7.0) | 11 (5.0) |
| **Education, n (%)** |  |  |  |  |  |  |
| Not degree level | 81 (27.9) | 83 (28.3) | 71 (28.5) | 72 (27.8) | 60 (27.9) | 65 (29.5) |
| Degree level or higher | 209 (72.1) | 210 (71.7) | 178 (71.5) | 187 (72.2) | 155 (72.1) | 155 (70.5) |
| **Household income, n (%)** |  |  |  |  |  |  |
| Lowest quintile | 5 (1.7) | 2 (0.7) | 4 (1.6) | 2 (0.8) | 3 (1.4) | 2 (0.9) |
| Second quintile | 21 (7.2) | 22 (7.5) | 19 (7.6) | 21 (8.0) | 19 (8.9) | 19 (8.6) |
| Third quintile | 69 (23.8) | 55 (18.8) | 64 (25.7) | 44 (17.0) | 54 (25.1) | 38 (17.3) |
| Fourth quintile | 93 (32.1) | 109 (37.2) | 76 (30.5) | 101 (39.0) | 63 (29.3) | 85 (38.6) |
| Highest quintile | 92 (31.7) | 92 (31.4) | 77 (30.9) | 81 (31.3) | 68 (31.6) | 66 (30.0) |
| Unavailable | 10 (3.5) | 13 (4.4) | 9 (3.6) | 10 (3.9) | 8 (3.7) | 10 (4.6) |
| **Smoking, n (%)** |  |  |  |  |  |  |
| Never smoked | 225 (78.4) | 237 (81.4) | 195(79.3) | 212 (82.1) | 174 (82.1) | 180 (82.2) |
| Previous smoker | 50 (17.4) | 43 (14.8) | 40 (16.3) | 36 (14.0) | 30 (14.1) | 30 (13.7) |
| Active smoker | 12 (4.2) | 11 (3.8) | 11 (4.5) | 10 (3.9) | 8 (3.8) | 9 (4.1) |
| **Nulliparous, n (%)** | 199 (68.6) | 170 (58.0) | 177(71.1) | 159 (61.4) | 148 (68.8) | 125 (56.8) |
| **Previous cesarean section (denominator - all parous women), n (%)** | 29 (31.9) | 32 (26.0) | 14 (19.4) | 15 (15.0) | 11 (16.4) | 11 (11.6) |
| **Preconception plasma glucose [mmol/L; median (IQR)] in a 75g oral glucose tolerance test** | | | | | | |
| Fasting | 4.9  (4.5 to 5.2) | 4.9  (4.6 to 5.2) | 4.9  (4.5 to 5.2) | 4.9  (4.6 to 5.2) | 4.9  (4.5 to 5.2) | 4.9  (4.5 to 5.2) |
| 2-hour | 5.4  (4.4 to 6.4) | 5.5  (4.6 to 6.3) | 5.4  (4.4 to 6.4) | 5.5  (4.6 to 6.3) | 5.3  (4.3 to 6.4) | 5.5  (4.6 to 6.3) |

Abbreviations: BMI, body mass index; IQR, interquartile range; n, number; SD, standard deviation

**Table 2: Effect of the NiPPeR intervention on blood loss, postpartum hemorrhage and blood transfusion**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **BLOOD LOSS** | **Control**  **Median (IQR)** | **Intervention**  **Median (IQR)** | **Effect of Intervention** | | | | | |
| **N** | **Adjusted mean difference**  **(95% CI)a,b** | **P**  **value** | **N** | **Fully-adjusted mean difference (95% CI)b,c** | **P**  **value** |
| Estimated blood loss at delivery (ml) | 350.0  (250.0, 500.0) | 300.0  (200.0, 425.0) | 561 | -42.0  (-77.0 to -10.5) | 0.012\* | 535 | -35.0  (-70.0 to -3.5) | 0.047\* |
| **POSTPARTUM HEMORRHAGE** | | | | | | | | |
| **Categories of PPH**d | **Control**  **N cases/total**  **(%)** | **Intervention**  **N cases/total**  **(%)** | **Effect of Intervention** | | | | | |
| **N** | **Adjusted RR**  **(95% CI)a** | **P**  **value** | **N** | **Fully-adjusted**  **RR (95% CI)c** | **P**  **value** |
| No PPH | 226/279 (81.0) | 231/282 (81.9) | 561 | Reference | … | 535 | Reference | … |
| Minor PPH (500-1000 ml) | 29/279 (10.4) | 42/282 (14.9) | 561 | 1.44 (0.85 to 2.45) | 0.171 | 535 | 1.64 (0.95 to 2.85) | 0.078 |
| Major PPH (>1000 ml) | 24/279 (8.6) | 9/282 (3.2) | 561 | 0.37  (0.16 to 0.82) | 0.015\* | 535 | 0.43  (0.19 to 0.99) | 0.048\* |
| **BLOOD TRANSFUSION** | | | | | | | | |
| Received blood transfusion | 7/286 (2.5) | 1/289 (0.3) | Insufficient cases for analysis | | | | | … |

aBasic model: Adjusted for site and ethnicity.

bLinear regression, loge-transformed for analyses, values presented are the calculated equivalent anti-log based on the median value in the control group, and represents estimated mean differences.

cFully-adjusted model: loge valuesadjusted for site, ethnicity, maternal age, pre-pregnancy BMI, household income deciles, parity, previous cesarean section history and smoking.

dMultinomial logistic regression analysis.

Statistically significant \*p<0.05.

Abbreviations: BMI, body mass index; CI, confidence interval; IQR, interquartile range; N, number; PPH, postpartum hemorrhage; RR, risk ratio.

**Figure legends:**

**Figure 1. Flowchart of study participants** from assessment of eligibility, through randomisation, conception and delivery. Abbreviation: cesarean, cesarean section delivery.

**Figure 2. Effect of the NiPPeR intervention on labor progress and oxytocin augmentation among those who labored.** (A) Unadjusted comparison of the duration of the three stages of labor between control and intervention groups by Mann-Whitney *U* test. Error bars denote the 95% CI of the mean. (B) Forest plot comparing the risk ratio (RR) between control and intervention groups for factors influencing labor progress. aBasic model: adjusted for site and ethnicity. bFully-adjusted model: adjusted for site, ethnicity, maternal age, pre-pregnancy BMI, household income deciles, parity, previous cesarean section history and smoking. cAdditionally adjusted for epidural use. dNot adjusted for parity as already taken into account by ACOG definition and treating clinician. eAdditionally adjusted for induction of labor; operative delivery includes cesarean section and instrumental vaginal deliveries .Statistically significant \*p<0.05, \*\*p<0.01. Only women with available data were included. Abbreviations: BMI, body mass index; CI, confidence interval; IQR, interquartile range; min, minutes; N, number; RR, risk ratio.